Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT Forward 1
2025-522492-28-00Phase 2Authorised
- Sponsor
- argenx
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label trial of empasiprubart and efgartigimod alfa in myasthenia gravis (MG) (2 arms), sponsored by argenx. Primary endpoints: Incidence, severity, and relatedness of adverse events and serious adverse events, Clinically meaningful changes in vital signs, ECGs, and laboratory parameters and 2 more. Planned start Mar 2026; status: authorised.
02
Drugs
empasiprubartefgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2025-522492-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522492-28-00.